These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7588990)

  • 1. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.
    Sam E; Jeanjean AP; Maloteaux JM; Verbeke N
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):27-33. PubMed ID: 7588990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of apomorphine in Parkinson's disease.
    Gancher S
    J Neural Transm Suppl; 1995; 45():137-41. PubMed ID: 8748619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between percutaneous and subcutaneous routes of administration of apomorphine in rabbit.
    Durif F; Beyssac E; Coudoré F; Paire M; Eschalier A; Aiache M; Lavarenne J
    Clin Neuropharmacol; 1994 Oct; 17(5):445-53. PubMed ID: 9316694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
    LeWitt PA
    Neurology; 2004 Mar; 62(6 Suppl 4):S8-11. PubMed ID: 15037665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
    Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
    Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T; Neef C; Danhof M; Roon KI; Roos RA
    Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.
    Neef C; van Laar T
    Clin Pharmacokinet; 1999 Sep; 37(3):257-71. PubMed ID: 10511920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
    van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
    Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits.
    Ikechukwu Ugwoke M; Sam E; Van Den Mooter G; Verbeke N; Kinget R
    Int J Pharm; 1999 Apr; 181(1):125-38. PubMed ID: 10370209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients.
    Thijssen E; Tuk B; Cakici M; van Velze V; Klaassen E; Merkus F; van Laar T; Kremer P; Groeneveld GJ
    Clin Transl Sci; 2024 May; 17(5):e13796. PubMed ID: 38712716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral pharmacokinetics of apomorphine in humans.
    Gancher ST; Woodward WR; Boucher B; Nutt JG
    Ann Neurol; 1989 Aug; 26(2):232-8. PubMed ID: 2774511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of apomorphine in the treatment of Parkinson's disease.
    Boyle A; Ondo W
    CNS Drugs; 2015 Feb; 29(2):83-9. PubMed ID: 25676564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption of apomorphine by various routes in parkinsonism.
    Gancher ST; Nutt JG; Woodward WR
    Mov Disord; 1991; 6(3):212-6. PubMed ID: 1922125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of apomorphine in parkinsonian patients.
    Nicolle E; Pollak P; Serre-Debeauvais F; Richard P; Gervason CL; Broussolle E; Gavend M
    Fundam Clin Pharmacol; 1993; 7(5):245-52. PubMed ID: 8370571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.
    van der Geest R; van Laar T; Kruger PP; Gubbens-Stibbe JM; Boddé HE; Roos RA; Danhof M
    Clin Neuropharmacol; 1998; 21(3):159-68. PubMed ID: 9617507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apomorphine in advanced Parkinson disease].
    Bogucki A
    Neurol Neurochir Pol; 2013; 47(5):476-83. PubMed ID: 24166569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
    Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.